

THE LANCET Summit

Chronic Obstructive Pulmonary Disease and Lung Cancer

July 28-29, 2017 | Perth, Australia

Programme

Friday July 28, 2017	
08.00 - 09.35	Session 1 – Prevention of COPD and lung cancer Effectiveness of smoking cessation strategies Renee Bittoun, <i>University of Sydney, Australia</i> Reducing exposures to air pollution and HAP Steven Gordon, <i>Liverpool School of Tropical Medicine, UK</i> The mining industry and risk of lung diseases Malcolm Sim, <i>Monash University, Australia</i> Early life exposures and development of lung diseases Peter D Sly, <i>The University of Queensland, Australia</i>
09.40 - 10.20	Plenary talk Governmental action on tobacco to drive public health change Mike Daube, <i>Curtin University, Australia</i>
10.25 - 11.05	Coffee
11.10 - 12.20	Session 2 – Screening for COPD and lung cancer Early detection of lung cancer in primary care: symptomatic vs screening detected cases Jon Emery, <i>University of Melbourne, Australia</i> Controversies in screening vs case finding for COPD Guy Marks, <i>University of New South Wales, Australia</i> Shared lessons from screening programmes, case finding initiatives, and predictive risk models in the diagnosis of COPD and lung cancer Harry de Koning, <i>Erasmus Medical Center, The Netherlands</i>
12.25 -13.55	Lunch Industry symposium
14.00 - 15.35	Session 3 – Genetic insights into disease development and patient management Lung cancer and COPD: shared genetic pathways to disease development. Guy Brusselle, <i>Ghent University Hospital, Belgium</i> COPD and lung cancer in never smokers Ian Yang, <i>The Prince Charles Hospital and The University of Queensland, Australia</i> Metabolic and nutritional aspects in relation to disease development in chronic lung diseases Annemie Schols, <i>Maastricht University, The Netherlands</i> COPD phenotypes: are they useful for patient management? Christine Jenkins, <i>Concord Hospital and University of Sydney, Australia</i>
15.40 – 16.20	Tea
16.20 - 17.20	Industry symposium
17.20 - 18.15	Session 4 – COPD and lung cancer: latest insights into treatment paradigms Immunotherapy and response biomarkers to treatment in lung cancer Paul Mitchell, <i>Austin Health, Victoria, Australia</i> COPD treatment: new treatment paradigms? Christine Jenkins, <i>Concord Hospital and University of Sydney, Australia</i>
18.20 - 20.20	Poster session and light refreshments

Saturday July 29, 2017	
08.00 - 09.15	Session 5 – Infectious complications in patient management Overprescribing of antibiotic treatment and development of resistance, who to treat and when? Grant Waterer, <i>University of Western Australia, Australia</i> Infection as risk factor for exacerbations in COPD: preventing re-hospitalisations John Upham, <i>The University of Queensland, Australia</i> Treatment-related infections in patients with lung cancer Paul Mitchell, <i>Austin Health, Victoria, Australia</i>
09.20 - 10.05	Plenary talk 2 The importance of comorbidities in COPD and Lung Cancer Barry Make, <i>National Jewish Health, USA</i>
10.10 - 10.50	Coffee
10.55 - 12.15	Overview of ongoing trials from the clinical trials groups
12.20 - 13.50	Lunch Industry symposium
13.55 - 14.40	Plenary talk 3 Lung transplantation for patients with lung diseases (lung cancer/IPF): current considerations in patient management Allan Glanville, <i>University of New South Wales and St Vincent's Hospital, Australia</i>
14.45 - 15.25	Tea
15.30 - 16.30	Industry symposium
16.35 - 17.45	Session 7 – Latest advances in surgery and radiation Use of ECMO in lung transplantation Marcelo Cypel, <i>University of Toronto, Canada</i> Advanced surgical techniques (particularly thoracoscopic or robotic) Peter Licht, <i>Odense University Hospital and University of Southern Denmark, Denmark</i> Latest concepts in radiation therapy for lung cancer: SABR for lung cancer and oligometastases Suresh Senan, <i>VU University Medical Center, The Netherlands</i>
17.50 - 18.40	Closing plenary talk: Post treatment and end of life care Palliative and end of life care in an integrated health care system Stein Kaasa, <i>Norwegian University of Science and Technology, Norway</i>